Hasmim, Meriem

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation

Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine

Cancer Immunotherapy and BiomarkersImmune cells in cancer

Cited by 2,166

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy

Noman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., et al. (2020) · Science Advances

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 255

The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200

Noman, M. Z., Janji, B., Abdou, A., Hasmim, M., Terry, S., Tan, T. Z., Mami-Chouaib, F., Thiery, J. P., & Chouaib, S. (2017) · OncoImmunology

Cancer Immunotherapy and BiomarkersCancer Cells and Metastasis

Cited by 253

The Cooperative Induction of Hypoxia-Inducible Factor-1α and STAT3 during Hypoxia Induced an Impairment of Tumor Susceptibility to CTL-Mediated Cell Lysis

Noman, M. Z., Buart, S., Van Pelt, J., Richon, C., Hasmim, M., Leleu, N., Suchorska, W. M., Jalil, A., Lecluse, Y., El Hage, F., et al. (2009) · The Journal of Immunology

Cancer, Hypoxia, and MetabolismCancer Immunotherapy and Biomarkers

Cited by 183

Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel–Lindau gene mutation status

Messai, Y., Gad, S., Noman, M. Z., Le Teuff, G., Couve, S., Janji, B., Kammerer, S. F., Rioux-Leclerc, N., Hasmim, M., Ferlicot, S., et al. (2016) · European Urology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 168

Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death

Bezzi, M., Hasmim, M., Bieler, G., Dormond, O., & Rüegg, C. (2003) · Journal of Biological Chemistry

Bone health and treatmentsCell death mechanisms and regulation

Cited by 139

Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy

Lequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., et al. (2021) · Oncogene

Cancer Immunotherapy and BiomarkersCancer, Hypoxia, and Metabolism

Cited by 129

ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy

Messai, Y., Noman, M. Z., Hasmim, M., Janji, B., Tittarelli, A., Boutet, M., Baud, V., Viry, E., Billot, K., Nanbakhsh, A., et al. (2014) · Cancer Research

Immune Cell Function and InteractionAutophagy in Disease and Therapy

Cited by 119

Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints

Lequeux, A., Noman, M. Z., Xiao, M., Sauvage, D., Van Moer, K., Viry, E., Bocci, I., Hasmim, M., Bosseler, M., Berchem, G., et al. (2019) · Cancer Letters

Cancer Immunotherapy and BiomarkersCancer Cells and Metastasis

Cited by 117

Firing up the cold tumors by targeting Vps34

Janji, B., Hasmim, M., Parpal, S., Berchem, G., & Noman, M. Z. (2020) · OncoImmunology

Cancer Immunotherapy and BiomarkersAutophagy in Disease and Therapy

Cited by 30